Skip to main content Accessibility help
×
×
Home

On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes

  • Robert Busch (a1), Alessandra De Riva (a1), Andreas V. Hadjinicolaou (a1) (a2), Wei Jiang (a2), Tieying Hou (a2) and Elizabeth D. Mellins (a2)...

Abstract

This review discusses mechanisms that link allelic variants of major histocompatibility complex (MHC) class II molecules (MHCII) to immune pathology. We focus on HLA (human leukocyte antigen)-DQ (DQ) alleles associated with celiac disease (CD) and type 1 diabetes (T1D) and the role of the murine DQ-like allele, H2-Ag7 (I-Ag7 or Ag7), in murine T1D. MHCII molecules bind peptides, and alleles vary in their peptide-binding specificity. Disease-associated alleles permit binding of disease-inducing peptides, such as gluten-derived, Glu-/Pro-rich gliadin peptides in CD and peptides from islet autoantigens, including insulin, in T1D. In addition, the CD-associated DQ2.5 and DQ8 alleles are unusual in their interactions with factors that regulate their peptide loading, invariant chain (Ii) and HLA-DM (DM). The same alleles, as well as other T1D DQ risk alleles (and Ag7), share nonpolar residues in place of Asp at β57 and prefer peptides that place acidic side chains in a pocket in the MHCII groove (P9). Antigen-presenting cells from T1D-susceptible mice and humans retain CLIP because of poor DM editing, although underlying mechanisms differ between species. We propose that these effects on peptide presentation make key contributions to CD and T1D pathogenesis.

Copyright

Corresponding author

*Corresponding author: Robert Busch, Division of Rheumatology, Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. E-mail: rb468@medschl.cam.ac.uk or Elizabeth D. Mellins, CCSR 2105c Stanford School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA. E-mail: mellins@stanford.edu

References

Hide All
1Carpenter, C.B. (1982) Autoimmunity and HLA. Journal of Clinical Immunology 2, 157-165
2Klein, J. (1986) Natural History of the Major Histocompatibility Complex, John Wiley & Sons, New York
3Ting, J.P. and Trowsdale, J. (2002) Genetic control of MHC class II expression. Cell 109 (Suppl), S21-S33
4Marsh, S.G. et al. (2010) Nomenclature for factors of the HLA system, 2010. Tissue Antigens 75, 291-455
5Neefjes, J. et al. (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology 11, 823-836
6Suri, A., Lovitch, S.B. and Unanue, E.R. (2006) The wide diversity and complexity of peptides bound to class II MHC molecules. Current Opinion in Immunology 18, 70-77
7Velazquez, C., DiPaolo, R. and Unanue, E.R. (2001) Quantitation of lysozyme peptides bound to class II MHC molecules indicates very large differences in levels of presentation. Journal of Immunology 166, 5488-5494
8Rammensee, H.G., Friede, T. and Stevanoviic, S. (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228
9Anderson, M.S. et al. (2002) Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395-1401
10Morris, G.P. and Allen, P.M. (2012) How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nature Immunology 13, 121-128
11Liston, A. and Rudensky, A.Y. (2007) Thymic development and peripheral homeostasis of regulatory T cells. Current Opinion in Immunology 19, 176-185
12Vukmanovic-Stejic, M. et al. (2011) Measurement of proliferation and disappearance of regulatory T cells in human studies using deuterium-labeled glucose. Methods in Molecular Biology 707, 243-261
13De Riva, A. et al. (2007) Noncognate interaction with MHC class II molecules is essential for maintenance of T cell metabolism to establish optimal memory CD4 T cell function. Journal of Immunology 178, 5488-5495
14Zygmunt, B. and Veldhoen, M. (2011) T helper cell differentiation: more than just cytokines. Advances in Immunology 109, 159-196
15Di Lorenzo, T.P., Peakman, M. and Roep, B.O. (2007) Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clinical and Experimental Immunology 148, 1-16
16Busch, R. and Mellins, E.D. (1996) Developing and shedding inhibitions: how MHC class II molecules reach maturity. Current Opinion in Immunology 8, 51-58
17Busch, R. et al. (2000) Accessory molecules for MHC class II peptide loading. Current Opinion in Immunology 12, 99-106
18Cresswell, P. (1994) Assembly, transport, and function of MHC class II molecules. Annual Review of Immunology 12, 259-293
19Ghosh, P. et al. (1995) The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462
20Busch, R. et al. (1996) Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO Journal 15, 418-428
21Kropshofer, H., Vogt, A.B. and Hämmerling, G.J. (1995) Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proceedings of the National Academy of Sciences of the United States of America 92, 8313-8317
22Sloan, V.S. et al. (1995) Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375, 802-806
23Denzin, L.K. and Cresswell, P. (1995) HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82, 155-165
24Sherman, M.A., Weber, D.A. and Jensen, P.E. (1995) DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3, 197-205
25Fremont, D.H. et al. (1998) Crystal structure of mouse H2-M. Immunity 9, 385-393
26Busch, R. et al. (1998) Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. Journal of Biological Chemistry 273, 27557-27564
27Pashine, A. et al. (2003) Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19, 183-192
28Vogt, A.B. et al. (1997) HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion. Immunology Letters 57, 209-211
29Denzin, L.K., Hammond, C. and Cresswell, P. (1996) HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. Journal of Experimental Medicine 184, 2153-2165
30Hsing, L.C. and Rudensky, A.Y. (2005) The lysosomal cysteine proteases in MHC class II antigen presentation. Immunological Reviews 207, 229-241
31Costantino, C.M. et al. (2008) Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation. Journal of Immunology 180, 2876-2885
32Reich, M. et al. (2011) Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells. Cellular Immunology 269, 96-103
33Denzin, L.K. et al. (1997) Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278, 106-109
34van Ham, S.M. et al. (1997) HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Current Biology 7, 950-957
35Kasai, M. et al. (2000) CLIP-derived self peptides bound to MHC class II molecules of medullary thymic epithelial cells differ from those of cortical thymic epithelial cells in their diversity, length, and C-terminal processing. European Journal of Immunology 30, 3542-3551
36Santambrogio, L. et al. (1999) Extracellular antigen processing and presentation by immature dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 96, 15056-15061
37Shin, J.S. et al. (2006) Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 444, 115-118
38Lightstone, L. et al. (1997) In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proceedings of the National Academy of Sciences of the United States of America 94, 5772-5777
39Katz, J.F. et al. (1996) Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. Journal of Experimental Medicine 184, 1747-1753
40Busch, R. et al. (2005) Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunological Reviews 207, 242-260
41Sette, A. et al. (1995) Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. Journal of Experimental Medicine 181, 677-683
42Koonce, C.H. et al. (2003) DM loss in k haplotype mice reveals isotype-specific chaperone requirements. Journal of Immunology 170, 3751-3761
43Rinderknecht, C.H. et al. (2007) Posttranslational regulation of I-Ed by affinity for CLIP. Journal of Immunology 179, 5907-5915
44Rinderknecht, C.H. et al. (2010) I-Ag7 is subject to post-translational chaperoning by CLIP. International Immunology 22, 705-716
45Green, P.H. and Cellier, C. (2007) Celiac disease. New England Journal of Medicine 357, 1731-1743
46Halstensen, T.S. and Brandtzaeg, P. (1993) Activated T lymphocytes in the celiac lesion: non-proliferative activation (CD25) of CD4+ alpha/beta cells in the lamina propria but proliferation (Ki-67) of alpha/beta and gamma/delta cells in the epithelium. European Journal of Immunology 23, 505-510
47Houlston, R.S. and Ford, D. (1996) Genetics of coeliac disease. QJM 89, 737-743
48Dubois, P.C. et al. (2010) Multiple common variants for celiac disease influencing immune gene expression. Nature Genetics 42, 295-302
49Sollid, L.M. et al. (1989) Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. Journal of Experimental Medicine 169, 345-350
50Spurkland, A. et al. (1990) Susceptibility to develop celiac disease is primarily associated with HLA-DQ alleles. Human Immunology 29, 157-165
51Spurkland, A. et al. (1997) Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 49, 29-34
52Johnson, T.C. et al. (2004) Relationship of HLA-DQ8 and severity of celiac disease: comparison of New York and Parisian cohorts. Clinical Gastroenterology and Hepatology 2, 888-894
53Harmon, G.S., Lebeck, L.K. and Weidner, N. (2011) Gluten-dependent enteropathy and atypical human leukocyte antigen alleles. Human Pathology 42, 1112-1116
54Schirru, E. et al. (2011) High frequency of low-risk human leukocyte antigen class II genotypes in latent celiac disease. Human Immunology 72, 179-182
55Hausch, F. et al. (2002) Intestinal digestive resistance of immunodominant gliadin peptides. American Journal of Physiology Gastrointestinal and Liver Physiology 283, G996-G1003
56Shan, L. et al. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297, 2275-2279
57Hue, S. et al. (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21, 367-377
58Di Sabatino, A. et al. (2006) Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55, 469-477
59Molberg, O. et al. (1997) Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scandinavian Journal of Immunology 46, 103-109
60Gjertsen, H.A. et al. (1994) T cells from the peripheral blood of coeliac disease patients recognize gluten antigens when presented by HLA-DR, -DQ, or -DP molecules. Scandinavian Journal of Immunology 39, 567-574
61Vader, W. et al. (2003) The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proceedings of the National Academy of Sciences of the United States of America 100, 12390-12395
62Molberg, O. et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Medicine 4, 713-717
63Vader, L.W. et al. (2002) Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. Journal of Experimental Medicine 195, 643-649
64Fleckenstein, B. et al. (2002) Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. Journal of Biological Chemistry 277, 34109-34116
65van de Wal, Y. et al. (1998) Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. Journal of Immunology 161, 1585-1588
66Quarsten, H. et al. (1999) HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. European Journal of Immunology 29, 2506-2514
67Arentz-Hansen, H. et al. (2000) The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. Journal of Experimental Medicine 191, 603-612
68van de Wal, Y. et al. (1999) Glutenin is involved in the gluten-driven mucosal T cell response. European Journal of Immunology 29, 3133-3139
69Stepniak, D. et al. (2008) Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2. Journal of Immunology 180, 3268-3278
70Kim, C.Y. et al. (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proceedings of the National Academy of Sciences of the United States of America 101, 4175-4179
71Bergseng, E. et al. (2005) Main chain hydrogen bond interactions in the binding of proline-rich gluten peptides to the celiac disease-associated HLA-DQ2 molecule. Journal of Biological Chemistry 280, 21791-21796
72Tollefsen, S. et al. (2006) HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. Journal of Clinical Investigation 116, 2226-2236
73Henderson, K.N. et al. (2007) A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 27, 23-34
74Margaritte-Jeannin, P. et al. (2004) HLA-DQ relative risks for coeliac disease in European populations: a study of the European Genetics Cluster on Coeliac Disease. Tissue Antigens 63, 562-567
75Qiao, S.W. et al. (2005) Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. Journal of Immunology 175, 254-261
76van de Wal, Y. et al. (1997) Unique peptide binding characteristics of the disease-associated DQ(alpha 1*0501, beta 1*0201) vs the non-disease-associated DQ(alpha 1*0201, beta 1*0202) molecule. Immunogenetics 46, 484-492
77Fallang, L.E. et al. (2009) Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nature Immunology 10, 1096-1101
78Fallang, L.E. et al. (2008) Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM. Journal of Immunology 181, 5451-5461
79Wiesner, M. et al. (2008) Dominance of an alternative CLIP sequence in the celiac disease associated HLA-DQ2 molecule. Immunogenetics 60, 551-555
80Hou, T. et al. (2011) An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. Journal of Immunology 187, 2442-2452
81Miyazaki, T. et al. (1996) Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84, 531-541
82Falk, K. et al. (2002) Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. Journal of Biological Chemistry 277, 2709-2715
83Marietta, E.V., David, C.S. and Murray, J.A. (2011) Important lessons derived from animal models of celiac disease. International Reviews of Immunology 30, 197-206
84Daneman, D. (2006) Type 1 diabetes. Lancet 367, 847-858
85Davies, J.L. et al. (1994) A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371, 130-136
86Tisch, R. and McDevitt, H. (1996) Insulin-dependent diabetes mellitus. Cell 85, 291-297
87Todd, J.A., Bell, J.I. and McDevitt, H.O. (1987) HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329, 599-604
88Wucherpfennig, K.W. (2003) MHC-linked susceptibility to type 1 diabetes: a structural perspective. Annals of the New York Academy of Sciences 1005, 119-127
89Khalil, I. et al. (1990) A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. Journal of Clinical Investigation 85, 1315-1319
90Cucca, F. et al. (2001) A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Human Molecular Genetics 10, 2025-2037
91Polychronakos, C. and Li, Q. (2011) Understanding type 1 diabetes through genetics: advances and prospects. Nature Reviews. Genetics 12, 781-792
92Nejentsev, S. et al. (2007) Localization of type I diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450, 887-892
93Barrett, J.C. et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genetics 41, 703-707
94Nichols, J. and Cooke, A. (2009) Overcoming self-destruction in the pancreas. Current Opinion in Biotechnology 20, 511-515
95Mallone, R., Brezar, V. and Boitard, C. (2011) T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clinical and Developmental Immunology 2011, 513210.
96Makino, S. et al. (1980) Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1-13
97Makino, S. et al. (1986) Absence of insulitis and overt diabetes in athymic nude mice with NOD genetic background. Jikken Dobutsu 35, 495-498
98Matsumoto, M. et al. (1993) Transfer of autoimmune diabetes from diabetic NOD mice to NOD athymic nude mice: the roles of T cell subsets in the pathogenesis. Cellular Immunology 148, 189-197
99Acha-Orbea, H. and McDevitt, H.O. (1987) The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proceedings of the National Academy of Sciences of the United States of America 84, 2435-2439
100Boitard, C. et al. (1988) Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proceedings of the National Academy of Sciences of the United States of America 85, 9719-9723
101Quartey-Papafio, R. et al. (1995) Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. Journal of Immunology 154, 5567-5575
102Lund, T. et al. (1990) Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 345, 727-729
103Hattori, M. et al. (1986) The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 231, 733-735
104Pelegri, C. et al. (2001) Islet endocrine-cell behavior from birth onward in mice with the nonobese diabetic genetic background. Molecular Medicine 7, 311-319
105Strid, J. et al. (2001) A defect in bone marrow derived dendritic cell maturation in the nonobese diabetic mouse. Clinical and Experimental Immunology 123, 375-381
106Durant, S. et al. (2002) Nonobese diabetic (NOD) mouse dendritic cells stimulate insulin secretion by prediabetic islets. Autoimmunity 35, 449-455
107Rolf, J. et al. (2005) The enlarged population of marginal zone/CD1d(high) B lymphocytes in nonobese diabetic mice maps to diabetes susceptibility region Idd11. Journal of Immunology 174, 4821-4827
108Marino, E. et al. (2008) Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 57, 395-404
109Serreze, D.V. et al. (1996) B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. Journal of Experimental Medicine 184, 2049-2053
110Mohan, J.F. et al. (2010) Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nature Immunology 11, 350-354
111Baker, F.J. et al. (2002) Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proceedings of the National Academy of Sciences of the United States of America 99, 9374-9379
112Gelber, C. et al. (1994) Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes 43, 33-39
113Mannering, S.I. et al. (2005) The insulin A-chain epitope recognized by human T cells is posttranslationally modified. Journal of Experimental Medicine 202, 1191-1197
114Mohan, J.F., Petzold, S.J. and Unanue, E.R. (2011) Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. Journal of Experimental Medicine 208, 2375-2383
115Suri, A., Levisetti, M.G. and Unanue, E.R. (2008) Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity? Current Opinion in Immunology 20, 105-110
116Stadinski, B.D. et al. (2010) Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunology 11, 225-231
117Fairchild, P.J. et al. (1993) An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. International Immunology 5, 1151-1158
118Sant, A.J. et al. (2005) The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunological Reviews, 207, 261-278
119Ridgway, W.M. et al. (1998) Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response. Journal of Experimental Medicine 188, 2267-2275
120Kanagawa, O. et al. (1998) Autoreactivity of T cells from nonobese diabetic mice: an I-Ag7-dependent reaction. Proceedings of the National Academy of Sciences of the United States of America 95, 1721-1724
121Mangialaio, S. et al. (1999) The arthritogenic T cell receptor and its ligand in a model of spontaneous arthritis. Arthritis and Rheumatism 42, 2517-2523
122Mingueneau, M. et al. (2012) Thymic negative selection is functional in NOD mice. Journal of Experimental Medicine 209, 623-637
123Mellanby, R.J. et al. (2008) Both central and peripheral tolerance mechanisms play roles in diabetes prevention in NOD-E transgenic mice. Autoimmunity 41, 383-394
124Stratmann, T. et al. (2000) The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. Journal of Immunology 165, 3214-3225
125Corper, A.L. et al. (2000) A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288, 505-511
126Carrasco-Marin, E. et al. (1996) The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. Journal of Immunology 156, 450-458
127Reich, E.P. et al. (1994) Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. Journal of Immunology 152, 2279-2288
128Suri, A. et al. (2005) Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. Journal of Clinical Investigation 115, 2268-2276
129Suri, A. et al. (2003) Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: the lack of competition. Proceedings of the National Academy of Sciences of the United States of America 100, 5330-5335
130Suri, A. et al. (2008) First signature of islet beta-cell-derived naturally processed peptides selected by diabetogenic class II MHC molecules. Journal of Immunology 180, 3849-3856
131Reizis, B. et al. (1997) Molecular characterization of the diabetes-associated mouse MHC class II protein, I-Ag7. International Immunology 9, 43-51
132Nalefski, E.A., Shaw, K.T. and Rao, A. (1995) An ion pair in class II major histocompatibility complex heterodimers critical for surface expression and peptide presentation. Journal of Biological Chemistry 270, 22351-22360
133Hausmann, D.H. et al. (1999) pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH. Journal of Experimental Medicine 189, 1723-1734
134Peterson, M. and Sant, A.J. (1998) The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM. Journal of Immunology 161, 2961-2967
135Bhatnagar, A. et al. (2001) Nonobese diabetic mice display elevated levels of class II-associated invariant chain peptide associated with I-Ag7 on the cell surface. Journal of Immunology 166, 4490-4497
136Silva, D.G. et al. (2004) Elevated lymphocyte expression of CLIP is associated with type 1 diabetes and may be a useful marker of autoimmune susceptibility. Annals of the New York Academy of Sciences 103, 765-68.
137Yan, G. et al. (2003) Impaired processing and presentation by MHC class II proteins in human diabetic cells. Journal of Immunology 170, 620-627
138Lich, J.D. et al. (2003) Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. Journal of Immunology 171, 853-859
139Arneson, L.S., Peterson, M. and Sant, A.J. (2000) The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent. Journal of Immunology 165, 2059-2067
140Marleau, A.M., Summers, K.L. and Singh, B. (2008) Differential contributions of APC subsets to T cell activation in nonobese diabetic mice. Journal of Immunology 180, 5235-5249
141Morris, P. et al. (1994) An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368, 551-554
142Germain, R.N. and Rinker, A.G. Jr. (1993) Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363, 725-728
143Ettinger, R.A. et al. (1998) Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. Journal of Immunology 161, 6439-6445
144Mellanby, R.J. et al. (2006) Loss of invariant chain protects nonobese diabetic mice against type 1 diabetes. Journal of Immunology 177, 7588-7598
145Koonce, C.H. and Bikoff, E.K. (2004) Dissecting MHC class II export, B cell maturation, and DM stability defects in invariant chain mutant mice. Journal of Immunology 173, 3271-3280
146Yi, W. et al. (2010) Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. Journal of Clinical Investigation 120, 1324-1336
147Yoshida, K. et al. (2010) The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity. Journal of Clinical Investigation 120, 1578-1590
148Klareskog, L. et al. (2006) Genes, environment and immunity in the development of rheumatoid arthritis. Current Opinion in Immunology 18, 650-655
149Lee, H.S. et al. (2008) Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Molecular Medicine 14, 293-300
150Louis-Plence, P. et al. (2000) The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism. Journal of Immunology 165, 4861-4869
151Toussirot, E. et al. (2000) The association of HLA-DM with rheumatoid arthritis in eastern France. Human Immunology 61, 303-308
152De Riva, A. et al. (2010) Measurement of protein synthesis using heavy water labeling and peptide mass spectrometry: discrimination between major histocompatibility complex allotypes. Analytical Biochemistry 403, 1-12
153Busch, R. et al. (2006) Measurement of protein turnover rates by heavy water labeling of nonessential amino acids. Biochimica et Biophysica Acta 1760, 730-744
154Busch, R. et al. (2007) Measurement of cell proliferation by heavy water labeling. Nature Protocols 2, 3045-3057
155Schrodinger, L. 2010. The PyMOL Molecular Graphics System, Version 1.3r1
156Baker, N.A. et al. (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proceedings of the National Academy of Sciences of the United States of America 98, 10037-10041
157Dolinsky, T.J. et al. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Research 35(Web Server issue), W522-W525
158Dolinsky, T.J. et al. (2004) PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Research 32(Web Server issue), W665-W667
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed